BB BIOTECH AG
BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 2.75 (news with additional features)
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Media Release of March 16, 2017 BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 2.75 All proposals of BB Biotech AG’s Board of Directors were approved by shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a dividend of CHF 2.75 per share. Payment will be made on March 22, 2017, the date of record is March 21, 2017 and the ex-dividend date is March 20, 2017. Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another one-year term of office. Investor Relations b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79 423 22 28 Company profile Disclaimer Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=DMABCASLQD Document title: Media release
16.03.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
End of News | DGAP News Service |